LEO Pharma's Anzupgo cream gets labeling supplement approved by FDA
FDA approved a labeling supplement for Anzupgo (delgocitinib), LEO Pharma's topical cream, with status dated June 30, 2026.
LEO Pharma had one regulatory item logged this week.
- Anzupgo, a topical cream containing delgocitinib 2%, sponsored by LEO Pharma AS, received approval on a labeling supplement (submission number 4) under NDA219155.1 The submission status date is listed as 2026-06-30, with the approval letter dated 2026-07-02 and updated label and medication guide documents dated 2026-07-10.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.